The complex pathophysiology of the disease and the fact that pain is multidimensional represent significant challenges for drug development in oncology.
ANS Biotech has set up a strategy for the preclinical development of your candidate in this field.
Together accelerate your research
Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.
Over 100 types of cancers affect humans. Among them, the most common types of cancer in males are lung cancer, prostate cancer and colorectal cancer whereas females experience most commonly breast cancer, colorectal cancer, lung cancer and cervical cancer. About 20% of males and 17% of females will get cancer at some point while 13% of males and 9% of females will die from it. This makes invasive cancer the leading cause of death in the developed world and the second leading cause in the developing world.
As of 2020, more than 18 million new cases occur annually and cancer caused about 9.6 million deaths.
Cancer can be detected by certain signs and symptoms or screening tests. It is then typically further investigated by medical imaging and confirmed by biopsy.
Cancer is often treated with some combination of radiation therapy, surgery, chemotherapy and targeted therapy. Pain and symptom management are an important part of care. Tumors cause pain by crushing or infiltrating tissue, triggering infection or inflammation, or releasing chemicals that make normally non-painful stimuli painful. Invasion of bone by cancer is the most common source of cancer pain. It is characterized by a constant background pain and instances of spontaneous or movement-related exacerbation are frequently described as severe.
How we can help you
Prior to moving into the clinic, preclinical investigations are necessary to evidence the efficacy of your compound in the cancer pain area.
Within a preclinical pain project, four steps may be of value:
1- In terms of compound profiling, we can document the basics for your lead (dose range, side effects, plasma level, CNS exposure).
2- Using a screening approach, we can guide you in the selection of your candidate.
3- We can leverage a broad panel of disease models mimicking the pathophysiology mechanisms of cancer pain to characterize the efficacy of your candidate.
4- We can mitigate the risk associated with clinical development by comparing your candidate versus standard of care agents.